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Abstract
Vascular calcification is a frequent complication of atherosclerosis, diabetes and chronic kidney disease. In the latter group of patients, calcifica-
tion is commonly seen in tunica media where smooth muscle cells (SMC) undergo osteoblastic transformation. Risk factors such as elevated
phosphorus levels and vitamin D3 analogues have been identified. In the light of earlier observations by our group and others, we sought to inhi-
bit SMC calcification via induction of ferritin. Human aortic SMC were cultured using b-glycerophosphate with activated vitamin D3, or inorganic
phosphate with calcium, and induction of alkaline phosphatase (ALP) and osteocalcin as well as accumulation of calcium were used to monitor
osteoblastic transformation. In addition, to examine the role of vitamin D3 analogues, plasma samples from patients on haemodialysis who had
received calcitriol or paricalcitol were tested for their tendency to induce calcification of SMC. Addition of exogenous ferritin mitigates the trans-
formation of SMC into osteoblast-like cells. Importantly, pharmacological induction of heavy chain ferritin by 3H-1,2-Dithiole-3-thione was able
to inhibit the SMC transition into osteoblast-like cells and calcification of extracellular matrix. Plasma samples collected from patients after the
administration of activated vitamin D3 caused significantly increased ALP activity in SMC compared to the samples drawn prior to activated
vitamin D3 and here, again induction of ferritin diminished the osteoblastic transformation. Our data suggests that pharmacological induction of
ferritin prevents osteoblastic transformation of SMC. Hence, utilization of such agents that will cause enhanced ferritin synthesis may have
important clinical applications in prevention of vascular calcification.
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Introduction
Cardiovascular disease remains the major cause of mortality in
patients with chronic kidney disease (CKD) [1–3]. In this regard, vas-
cular calcification continues to be a significant clinical challenge with
detrimental consequences and its prevalence and progression is
rapidly accelerated once patients require renal replacement therapy
[4]. Two distinct forms of vascular calcification have been identified:
intimal and medial calcification. The intimal calcification is commonly
seen in atherosclerotic lesions, whereas calcification of the tunica
media, also known as M€onckeberg’s sclerosis, frequently accompa-
nies ageing, diabetes mellitus and advanced CKD [5]. The medial calci-
fication was once thought to be a passive and benign finding,
however, a strong body of evidence now suggests that medial calcifi-
cation is a major cause of mortality and morbidity as it causes vascular
stiffness, increases afterload with subsequent hypertrophy of the left
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ventricle and compromise of coronary perfusion [6]. Moreover, the
process of calcification of the vascular tree is now proven to be a deli-
cate and regulated cellular process that entails transdifferentiation of
SMC into osteoblast-like cells. One of the markers of this transition is
up-regulation of ALP [7, 8]. Alkaline phosphatase is a hydrolase
enzyme that is important in early osteogenesis and has been demon-
strated to hydrolyse and reduce the levels of a key inhibitor of hydrox-
yapatite formation namely, extracellular pyrophosphate. Given its
function and the fact that its induction has been shown to be a major
determinant of osteoblastic differentiation of SMC, ALP expression is
commonly used as a surrogate to monitor the initiation and degree of
vascular calcification [8]. Transition of SMC into osteoblast-like cells
is also indicated by the increase in expression of osteocalcin, a major
non-collagenous protein found in bone matrix which is believed to reg-
ulate mineralization [7]. Several promoters and inhibitors are now
identified that are actively involved in commencing and propagation of
vascular calcification [9]. One of the most potent recognized inducers
of vascular mineralization is elevated phosphorus (Pi) level. There is
compelling evidence from clinical, animal and in vitro studies that
hyperphosphataemia is a significant risk factor for the development of
vascular calcification in CKD patients [10–13]. Another culprit that has
been shown to induce calcification of SMC is excess of activated form
of vitamin D although different forms of vitamin D have been shown to
have different degree of effects on vascular calcification [14, 15].
Previously, we investigated whether induction of haeme oxyge-
nase-1/ferritin system alters high Pi-induced SMC calcification in vitro.
We found that iron (regardless of its ferric or ferrous state) released
from the haeme moiety attenuates calcium deposition of SMC in a
dose-responsive manner when SMC are cultured in the presence of
high Pi [16]. Further studies revealed that iron-induced ferritin heavy
chain (FtH) expression was responsible for the observed inhibitory
effects on calcium deposition. This notion was corroborated by utilizing
recombinant FtH protein and its mutant form [16, 17]. We found that
while addition of FtH (devoid of iron) was able to prevent mineraliza-
tion, the mutant form that lacks ferroxidase activity was ineffectual.
Severe decline in renal function and renal replacement therapy
requirement are commonly associated with not only hyperphos-
phataemia but also iron deficiency [18]. Major contributing factors to
such iron deficiency include blood loss during haemodialysis, bleed-
ing of cannula puncture sites following haemodialysis and too fre-
quent diagnostic blood tests. Moreover, during chronic inflammatory
diseases (such as CKD) there is an overproduction of a number of
cytokines that exert multiple functions including increased production
of hepcidin that in turn leads to the degradation of ferroportin (mem-
brane iron transporter) [19]. The overall effect translates to a ‘func-
tional iron deficiency’ state which subsequently leads to decreased
intracellular ferritin levels. Therefore, based on our previous studies
we concluded that iron deficiency and the ensuing decrement in intra-
cellular FtH expression facilitates vascular calcification in this group
of patients and it has been suggested that overexpression of FtH
would have inhibitory properties against mineralization of the vascula-
ture in advanced CKD. However, based on iron’s ability to readily
accept or donate electrons, it is well known that iron overload and
saturation of its sequestration threshold could lead to the generation
of reactive oxygen species and consequent injurious effects [20].
Hence, we sought to investigate whether 1,2-dithiole-3-thione (D3T),
a potent inhibitor of chemical-induced tumours and a strong inducer
of ferritin [21, 22], could be used to prevent calcification and
osteoblastic differentiation of SMC. 1,2-dithiole-3-thione has been
shown to induce ferritin expression irrespective of iron concentra-
tions via transcriptional mechanism that is mediated by the FtH elec-
trophile/antioxidant responsive element [22].
To examine this hypothesis we used human aortic SMC and
induced calcification by utilizing b-glycerophosphate (BGP) with vita-
min D3 analogues, as well as Pi with calcium.
Materials and Methods
Reagents
Calcitriol for in vitro experiments was purchased from Cayman Chemi-
cals (Ann Arbor, MI, USA) and fetal bovine serum (FBS) from Life Tech-
nologies (Vienna, Austria). Recombinant ferritin subunits: H, L, H222
mutant were provided by Dr. Paolo Arosio (Department M.I. and
Biomedical Technologies, University of Brescia, Brescia, Italy). Protease
inhibitor tablets were from Roche (Mannheim, Germany). Paricalcitol
(Zemplar) and calcitriol (Calcijex) for in vivo experiments were pur-
chased from commercial source. Unless otherwise mentioned, all other
reagents were purchased from Sigma-Aldrich.
Cell culture
Human aortic SMC were obtained from Cell Applications (San Diego,
CA, USA), Lonza (Allendale, NJ, USA), Cambrex (Wokingham, UK). We
used human SMC from one to five independent donors for our experi-
ments. We designated the number of independent donors used for each
figures that were more than one. Cells were grown in high glucose
DMEM containing 15% FBS, 1 mM sodium pyruvate, 100 U/ml peni-
cillin, 100 lg/ml streptomycin and neomycin (growth medium, GM).
Cells were grown to confluence and used from passages 5 to 7. Media
were changed every 2 days.
Alkaline phosphatase activity assay
Cells were grown on twelve-well plates for 7 days. Cells were washed
with PBS twice and then solubilized with solubilization buffer [1% Triton-
X 100, 0.5% Igepal CA-630, 1% protease inhibitor, 150 mM NaCl, 5 mM
ethylenediaminetetraacetic acid (EDTA), 10 mM Tris]. The assay was per-
formed by adding 35 ll sample to 130 ll of ALP Yellow Liquid Substrate
and the kinetics of p-nitrophenol formation was followed up for 30 min.
at 405 nm incubating at 37°C. Maximum slope of the kinetic curves was
used for calculation and the results were normalized to protein content.
Alkaline phosphatase activity staining
Cells were grown on 48-well plates for 7 days. Staining was done using
the 85L3R kit from Sigma-Aldrich. Briefly, cells were washed with PBS
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twice and fixed with citrate–acetone (2:3) solution. After fixation, cells
were washed with ddH2O twice. Staining step was performed with Fast
violet B salt containing 4% naphtol AS-MX for 30 min. in dark. After
staining, cells were washed again with ddH2O and images were obtained.
Quantification of calcium deposition
Cells grown on 48-well plates were washed twice with PBS and decalci-
fied with 0.6 mol/l HCl for 24 hrs at 37°C. Calcium content of the
supernatants was determined by the QuantiChrome Calcium Assay Kit
(Gentaur, Brussels, Belgium). After decalcification, cells were solubilized
with a solution of NaOH 0.1 mol/l and SDS 0.1%, and protein content
of samples was measured with (bicinchoninic acid) BCA protein assay
kit (Pierce, Rockford, IL, USA). Calcium content of the cells was nor-
malized to protein content and expressed as lg/mg protein. Mineraliza-
tion was also determined by Alizarin Red staining. Briefly, cells grown
on 48-well cell culture plates were washed with PBS and fixed with 4%
paraformaldehyde. Plates were incubated for 10 min. in RT. Cells were
washed with PBS and then stained with 2% Alizarin Red solution for
2 min. After the incubation cells were washed three times with distilled
water and photos were taken under light microscope.
Quantification of osteocalcin
Osteocalcin was detected from the extracellular matrix of cells grown
on six-well plates and was dissolved in 300 ll of EDTA [0.5 mol/l (pH
6.9)]. Osteocalcin content of the EDTA-solubilized extracellular matrix
samples was quantified by ELISA method (Bender MedSystems, Burlin-
game, CA, USA).
Western Blot for ALP and FtH
Western blotting was performed with 10% SDS-PAGE gels and
0.45 lm pore size nitrocellulose membrane (Amersham Biosciences,
Little Chalfont, UK). Alkaline phosphatase was detected with a rabbit
polyclonal antibody at 1:200 dilution (sc-30203; Santa Cruz Biotechnol-
ogy, Dallas, TX, USA) followed by HRP-labelled anti-rabbit IgG sec-
ondary antibody 1:15,000 (Amersham Biosciences). Ferritin heavy chain
was detected using primary antibody against human FtH at 1:400 dilu-
tion (sc-25617; Santa Cruz Biotechnology) and secondary antimouse
IgG antibody (Amersham Biosciences) was used at 1:15,000 dilution.
Antigen–antibody complexes were visualized with the horseradish per-
oxidase chemiluminescence system (Amersham Biosciences). Mem-
branes were reprobed for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Mouse anti-GAPDH (NB300-221; Novus Biologicals, Littleton,
CO, USA) at 1:1000 and secondary antimouse IgG (Amersham Bio-
sciences) at 1:15,000 dilution were used.
Quantitative reverse transcription-polymerase
chain reaction
Cells were grown on six-well plates and total RNA was isolated
with RNA-STAT60 (Tel-Test Inc, Friendswood TX, USA). SuperScript III
reverse transcriptase kit (Invitrogen, Carlsbad, CA, USA) with oligodT
(Promega, Madison, WI, USA) was used for reverse transcription. Alka-
line phosphatase mRNA expression was determined by multiplex Taq-
Man Gene Expression Assays and was normalized to GAPDH (ALP:
Hs00758162_m1; GAPDH: Hs99999905_m1; Applied Biosystem, Foster
City, CA, USA). A total of 20 ll of reaction mixture contained 10 ll Taq-
Man Gene Expression Mastermix (Applied Biosystem) and 1 ll of
assays from target and housekeeping gene and was completed with
8 ll of depc-treated water. Reverse transcriptions and qPCRs were car-
ried out using the C1000 Thermal Cycler with CFX 96 Real Time PCR
System (Bio-Rad, Hercules, CA, USA).
FtH siRNA transfection
Small interfering RNA specific to FtH and negative control siRNA were
obtained from Ambion (Austin, TX, USA). Smooth muscle cell transfec-
tion with siRNA was achieved using the Oligofectamine Reagent (Invit-
rogen). Briefly, the cells were plated overnight to form 60–70%
confluent monolayers. Ferritin heavy chain siRNA at 30 nmol/l and
transfection reagent complex were added to the cells in serum-free
medium for 4 hrs. Fresh normal GM was later added and the cells were
incubated for another 20 hrs.
In vivo study with different vitamin D receptor
(VDR) activators
This study included five patients with end-stage renal disease (ESRD)
who receive intermittent haemodialysis on a regular schedule three times
a week and suffer from secondary hyperparathyroidism. All patients met
the criteria for paricalcitol and calcitriol medication as suggested by the
guidelines of the Hungarian Society of Nephrology. Anticoagulated blood
samples were collected after the routine dialysis before and 10 min. after
the administration of drugs. The blood samples were centrifuged at
2000 9 g for 10 min. Plasma of the blood samples were collected and
kept frozen until the time of experiments when they were added to the
medium. Specifically cells were treated by a 50% ratio of patient’s plasma
and 50% of growing media without FBS for 5 days. Samples collected
after the drug administration were used with or without addition of apo-
ferritin for assessing ALP activity, thus exposure of SMC of apoferritin
lasted 5 days as well. The study design and patient care were reviewed
and permission was obtained by the Ethics Committee of the University
of Debrecen and the Hungarian Government.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5 and by one-
way ANOVA test followed by post hoc Bonferroni’s Multiple Comparison
test. A significant value of P < 0.05 was marked with *, P < 0.01 with
** and P < 0.001 was marked with ***. Non-significant (ns) differ-
ences were also marked. Data are shown as mean  SD.
Statistical analysis for Figure 9C was performed employing Statistica
for Windows. The variables were characterized by descriptive analyses
(case number, median, quartiles). After comparing the results with
Friedman ANOVA, we used Wilcoxon matched pair test with Bonferroni
correction to collate the paired samples. P ≤ 0.05 was considered
significant.
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Results
b-glycerophosphate and activated vitamin D3
promote osteoblast-like transformation of
vascular SMC
Our first goal was to test the osteoblast-like transformation of
human aortic SMC induced by BGP and activated vitamin D3 (Cal-
citriol). Both inducers have the ability to increase ALP activity in
dose-dependent manner. As expected we found that combined treat-
ment resulted in higher enzyme activity of ALP (Fig. 1A). The induc-
tion of enzyme activity was time-dependent leading to a pronounced
elevation at 7 days of exposure (Fig. 1B). Therefore, in our studies
the expression of ALP in human SMC was assessed at 7 days.
Staining for ALP activity showed increased number of positively
stained cells following treatment with BGP or calcitriol alone or
together (Fig. 1C). Western blots confirmed that the increased activ-
ity was because of the increment of ALP expression. b-glycerophos-
phate and calcitriol increased the enzyme level dose-dependently
and the additive effect is also evident in this representative experi-
ment (Fig. 1D). Expression of ALP protein was also estimated using
immunofluorescence staining. Untreated cells were almost com-
pletely negative with this staining, whereas cells exposed to BGP
and/or calcitriol show increased fluorescence signal indicating higher
expression. The cytoskeleton was counterstained for fibrillar actin
(Fig. 1E).
Ferritin mitigates induction of ALP activity
Human aortic SMC were treated with BGP and calcitriol alone or in
combination to investigate the induction of ALP in the presence or
absence of apo- and holoferritin. Both forms of ferritin decreased the
activity of ALP and our findings show that there were no significant
differences between the two forms (Fig. 2A). Based on this result that
elaborates both forms of ferritin are capable of marked inhibition of
ALP expression induced either by BGP or activated vitamin D3, the
subsequent experiments were performed with the combination of
both BPG and vitamin D3.
As ferritin shell is made of both the H and L chains and to delin-
eate the individual effects of each form of ferritin, we performed the
following experiment using H- (FtH) and L- recombinant ferritin. Fur-
thermore, we also utilized the H222 mutant form of FtH which is iden-
tical to the FtH, but lacks ferroxidase activity based on the mutation
[23]. Alkaline phosphatase activity assays showed that inhibition of
transformation only occurred when cells were pre-incubated with FtH
chain, whereas L chain and H222 (both of which lack ferroxidase
activity) had no effect (Fig. 2B).
Alkaline phosphatase staining of treated cells showed increased
number of positively stained cells treated with both inducing
agents versus untreated cells. Addition of either apo- or holofer-
ritin led to significant inhibition of ALP induction. In addition, fer-
ritin subunits were also used in staining assays to show the
inhibitory effect of ferroxidase activity. Inhibition of transformation
only occurred when cells were pre-incubated with ferroxidase-ac-
tive H chain (Fig. 2C).
To determine whether the effects of exposure of cells to exoge-
nous ferritins were specific for ferritin per se (as opposed to effects
which might be mediated by the fluid phase endocytosis of exoge-
nous ferritin), cells were also pre-exposed to iron (in the form of ferric
ammonium citrate) which induces ferritin synthesis by increasing
intracellular iron (Fig. 3B). The treatment of cells with iron and subse-
quent induction of ferritin resulted in mitigation of BGP and calcitriol-
induced ALP induction (Fig. 3A).
The specific involvement of ferritin in the prevention of ALP induc-
tion is supported by experiments using siRNA. Again, we exposed
cells to ferric ammonium citrate, but in this case, inhibited ferritin
synthesis using anti-FtH siRNA. The suppression of FtH induction
abrogated the blockade of ALP induction which proceeded in cells
which had not been pre-treated with BGP and calcitriol (Fig. 3C).
Therefore, these results demonstrate that FtH induction – irrespective
of the mode and whether via fluid phase endocytosis of exogenous
FtH or induction of FtH synthesis caused by exposure to additional
iron in the culture medium – directly prevents ALP expression and
activity which normally occurs under conditions favouring calcifica-
tion. We also confirmed the efficiency of siRNA, and observed an
approximately 80% decrease in FtH protein expression for up to
4 days after transfection (Fig. 3D).
Besides iron, which is the physiological inducer of ferritin, other
agents could also be utilized to induce endogenous ferritin expres-
sion. We chose the 3H-1,2-Dithiole-3-thione (D3T). Human aortic
SMC treated with increasing dose of D3T in the presence of BGP and
calcitriol showed lower activity of ALP, and the decreased enzyme
activity showed an inverse relationship with the increasing dosage of
D3T (Fig. 4A). We confirmed induction of FtH as a dose-dependent
response to D3T administration (Fig. 4B). To demonstrate that FtH
induction by D3T is responsible for the inhibitory effect on ALP
expression in SMC, we transfected cells with siRNA for FtH and mea-
sured ALP enzyme activity. Indeed, ALP activity was not attenuated in
D3T-treated SMC grown in BGP and calcitriol containing media after
silencing FtH (Fig. 4C). The efficiency of silencing FtH was approxi-
mately 70% (Fig. 4D) in our experiment.
Elucidation of mechanism of inhibition of human
aortic SMC differentiation to osteoblasts
We next sought to investigate the mechanism by which FtH provides
inhibitions of ALP and hence osteoblastic transformation of SMC. In
vitro measurement of enzyme activity was performed for which cells
were treated with BGP and calcitriol for 7 days and then solubilized.
Supernatant of cell lysates were exposed to the effect of apo- and
holoferritin. Levamisole, a well-known inhibitor of ALP was used to
illustrate the inhibition. We found that such a treatment did not result
in inhibition of ALP activity and hence results suggest thatferritin does
not directly alter ALP enzyme activity (Fig. 5A).
We then examined protein expression by Western blot. Cells
treated with calcifying media showed increased ALP expression,
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whereas both apo- and holoferritin diminished the induction
(Fig. 5B). Moreover, we show that ferritin molecules can inhibit
the increased level of ALP protein visualized with immunofluores-
cence staining (Fig. 5C).
Next, we examined the possibility of observed inhibitory
effects at transcriptional level utilizing RT-PCR. mRNA expres-
sions of ALP in samples were measured and normalized by
GAPDH and the fold increase to growth media was calculated.
We show that calcifying condition resulted in up-regulation of
ALP mRNA. Results revealed that both apo- and holoferritin sig-
nificantly decreased ALP mRNA levels (Fig. 5D). These results
indicate that regulation of ALP expression in SMC by ferritin
occurs at transcriptional level.
Ferroxidase activity is the key inhibitory
mediator of osteoblastic transformation
Ceruloplasmin is a copper-binding and carrier protein that is mainly
produced by hepatocytes. However, for the purposes of our experi-
ments it served as an important control arm as it, similar to FtH,
possesses ferroxidase activity. Ferroxidase activity of ceruloplasmin
dose-dependently inhibited the ALP activity enhanced by osteoblas-
tic inducers (Fig. 6A). Induction of ALP by calcitriol alone was also
inhibited by ceruloplasmin by 70%. Staining experiments also
demonstrated further evidence supporting the inhibitory role of fer-
roxidase activity (Fig. 6B). The decreased activity was caused by
Fig. 1 b-glycerophosphate (BGP) and activated vitamin D3 (calcitriol) induces the osteoblastic transformation of human aortic smooth muscle cells
(SMC). Human aortic SMC were cultured in growth medium (GM) or in the presence of increasing dose of BGP (5–10–20 mmol/l) with or without
low and high dose of calcitriol (10–100 nmol/l) for 7 days. (A) Alkaline phosphatase enzyme activity was measured, and the results were normalized
by protein content and data show the average of three separate experiments performed in duplicate from three independent donors. **P < 0.01,
***P < 0.001. (B) Cells from five independent donors were exposed to BGP with calcitriol for up to 3 weeks and enzyme activity was determined at
3, 5, 7, 14 and 21 days. (C) SMC were stained for alkaline phosphatase enzyme activity directly, and representative parts of the slides were
selected, magnification 1009. (D) Alkaline phosphatase enzyme level was detected by Western Blot, where loading control was performed by
GAPDH. (E) Alkaline phosphatase induction was visualized by immunofluorescence staining. Blue colour represents the nuclei, green is for the fibril-
lar actin and red for the alkaline phosphatase, magnification 4009.
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the lowered protein expression, which was detected by Western blot
analysis (Fig. 6C).
Inhibition of human aortic SMC mineralization by
heavy chain ferritin
Although the expression of ALP as an early marker of mineraliza-
tion was increased after exposure of human SMC to BGP and cal-
citriol mineralization did not occur even if cells from five
independent donors were cultured for up to 3 weeks. This is in
accordance with the literature – bovine SMC are mostly employed
in calcification studies as they are more ready to mineralize as
compared to human SMC. To demonstrate that by up-regulating
ferritin by iron or D3T inhibits not only the expression of ALP,
but it affects calcification as well in human SMC, we exposed
human aortic SMC to 1.2 mmol/l Pi and 0.9 mmol/l calcium (cal-
cification medium) and performed Alizarin red staining as well as
measured the calcium accumulation. Granular deposits developed
in cells grown in calcification medium, but not in the control cul-
ture grown in normal GM (Fig. 7A and D), as demonstrated by
Alizarin red staining. We found that addition of iron or D3T to the
calcification medium suppresses granular deposit development
(Fig. 7A and D) and extracellular calcium deposition in a dose-re-
sponsive manner (Fig. 7B and E), causing marked inhibition at
concentrations of 25 and 50 lmol/l, respectively. As iron is a very
potent inducer of ferritin and D3T also markedly enhances the
intracellular ferritin content (Figs 3 and 4), next we tested whether
the observed inhibitory effect of iron or D3T on calcium deposi-
tion is mimicked by apoferritin. We found that iron-free apoferritin
at a dose of 2 mg/ml abolishes granule formation (Fig. 7A) and
inhibits calcium deposition (Fig. 7B). To confirm the inhibitory
effect of iron or D3T on calcium accumulation occurs via FtH, we
transfected human SMC with small interfering RNA specific to
FtH. We observed an approximately 70% efficiency in FtH silenc-
ing (Fig. 8E). As we exposed cells to ferric ammonium citrate or
D3T the suppression of FtH induction resulted in abrogation of
the inhibition of calcium accumulation (Fig. 8A and C). This result
indicates that the elevation of intracellular FtH by iron or D3T is
the main mediator of inhibition of the calcification of extracellular
matrix.
Next we investigated the presence of the bone-specific protein,
osteocalcin, in the extracellular matrix. Maintaining of human SMC in
calcification medium for 7 days resulted in a significant increase in
Fig. 2 Ferritin inhibits the osteoblastic transformation of human aortic smooth muscle cells (SMC) induced by b-glycerophosphate (BGP) and acti-
vated vitamin D3 (calcitriol). (A) SMC were cultured in growth media (GM) or in the presence of BGP (10 mmol/l) with or without calcitriol
(10 nmol/l) with additional apo- or holoferritin (2 mg/ml) for 7 days. (B) SMC were cultured in GM or in the presence of BGP (10 mmol/l) and cal-
citriol (10 nmol/l) with different subunits of ferritin molecule, H-, L- and mutant H-chain respectively. After 7 days, alkaline phosphatase enzyme
activity was measured, and the results were normalized by protein content and data show the average of three separate experiments performed in
duplicate. ***P < 0.001. (C) SMC were cultured in GM or in the presence of BGP (10 mmol/l) and calcitriol (10 nmol/l) with additional apo- or
holoferritin or different subunits of ferritin molecule, H-, L- and mutant H-chain respectively for 7 days, and cells were stained for alkaline phos-
phatase enzyme activity directly, and representative parts of the slides were selected, magnification 1009.
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osteocalcin content compared to the control Figure 7C and F. Iron or
D3T decreased the up-regulation of osteocalcin in a dose-responsive
manner (Fig. 7C and F). In addition, apoferritin also abolished expres-
sion of osteocalcin (Fig. 7C). As we silenced FtH in human SMC trea-
ted with ferric ammonium citrate or D3T (Fig. 8E) the inhibition of
osteocalcin accumulation in extracellular matrix was abrogated
(Fig. 8B and D). Taken together, intracellular ferritin induction is a
major inhibitory mediator of calcification and transdifferentiation of
SMC.
Vitamin D3 receptor agonist in the osteoblastic
transformation
Paricalcitol was able to increase the activity of ALP in human aortic
SMC and the inducing effect was dose-dependent (Fig. 9A). Ferroxi-
dase activity of apo- and holoferritin inhibited the increased ALP
enzyme activity induced by paricalcitol (Fig. 9B).
In vivo study with different VDR activators and
ferritin
Plasma samples from patients with ESRD and secondary hyper-
parathyroidism who were treated with calcitriol or paricalcitol were
collected and added to human aortic SMC. After 5 days, calcitriol
significantly increased enzyme activity, and apoferritin abrogated this
induction. Paricalcitol also significantly induced the activity of ALP
albeit to a lesser degree. Again, addition of ferritin lowered ALP
activity to baseline level irrespective of the inducer (Fig. 9C).
Discussion
The findings presented in this study corroborate the inhibitory role of
FtH in the inhibition of SMC mineralization and osteoblastic transfor-
mation. To induce mineralization we used BGP with or without the
addition of calcitriol. These experiments confirmed previous reports
Fig. 3 Exogenous iron inhibits the osteoblastic transformation of human aortic smooth muscle cells (SMC) induced by b-glycerophosphate (BGP)
and activated vitamin D3 (calcitriol) by increased ferritin expression. SMC were cultured in growth medium (GM) or in the presence of BGP
(10 mmol/l) and calcitriol (10 nmol/l) with increasing dose of ferric-(III)-ammonium citrate (12.5–25–50–100 lmol/l) for 7 days. (A) Alkaline phos-
phatase enzyme activity was measured, and the results were normalized by protein content and data show the average of three separate experi-
ments performed in duplicate. ***P < 0.001. (B) Ferritin H-chain expression was detected by Western blot as shown in upper panel, and after
densitometry the result was normalized to GAPDH, shown in lower panel. *P < 0.05, **P < 0.01, ***P < 0.001 (C) SMC were cultured in GM or
in the presence of BGP (10 mmol/l) and calcitriol (10 nmol/l) with additional ferric-(III)-ammonium citrate (25 lmol/l) for 5 days with or without
negative control (NC) or H-ferritin (FtH)-specific siRNA. Alkaline phosphatase enzyme activity was measured, and the results were normalized by
protein content and data show the average of two separate experiments performed in duplicate. ***P < 0.001. (D) To evaluate the efficiency of fer-
ritin H-chain silencing protein expression was detected by Western blot shown in upper panel, and the results of densitometry after normalizing to
GAPDH are shown in lower panel.
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identifying elevated Pi and high levels of activated vitamin-D
(calcitriol) as inducers of calcification of SMC [15, 24, 25]. We used
ALP expression as a surrogate of SMC transition to osteoblasts as
previously reported [8]. We validated that FtH prevents calcification
and osteoblastic transformation of SMC, irrespective of the inducers
used in this study. In this regard, ferroxidase activity was confirmed
to be essential in the mitigation of calcification. We used D3T, a well-
known chemo-preventive agent that is known to induce ferritin
expression [21, 22].
We demonstrate that induction of ferritin via D3T abrogates SMC
transition to osteoblasts and therefore prevents calcification of
extracellular matrix (Fig. 10). Furthermore, we found that culture of
SMC with serum samples from ESRD patients receiving calcitriol or
paricalcitol leads to osteoblastic transition and we also show that
addition of FtH prevents such transition.
Cardiovascular disease remains the leading cause of death in
patients with advanced CKD and ESRD [2, 26, 27]. Evidence suggests
that adjusted cardiovascular attributed mortality is higher by about
10–20-fold in CKD patients compared to the general population [28].
The increased prevalence of cardiovascular disease in this group of
patients is, at least in part, attributable to vascular calcification [29].
Increased prevalence of this condition in the younger patient popula-
tion requiring renal replacement therapy is a strong confirmation that
the uraemic milieu generates the perfect storm for initiation and
acceleration of vascular calcification [30, 31]. Increased Pi level is a
significant risk factor and has been confirmed in multiple studies to
be a key regulator of vascular calcification [32]. Other inducers of
vascular calcification have also been identified [33]. The vitamin D
receptor analogues have been shown to induce mineralization of the
vascular tree as well. However, different analogues have been shown
to exert variable results [4, 14]. Importantly, calcitriol and its ana-
logues are routinely used to manage secondary hyperparathyroidsm
that is a frequent complication of end-stage kidney disease. The SMC
are known to express vitamin-D receptor that is up-regulated by cal-
citriol. Furthermore, previous studies indicate that calcitriol can exert
multiple effects on the proliferation and differentiation of SMC. In
addition, it has been demonstrated that supraphysiological doses of
calcitriol can induce vascular calcification in both in vitro and animal
Fig. 4 Pharmacological induction of ferritin inhibits the osteoblastic transformation of human aortic smooth muscle cells (SMC) induced by b-glyc-
erophosphate (BGP) and activated vitamin D3 (calcitriol). SMC were cultured in the growth medium (GM) or in the presence of BGP (10 mmol/l)
and calcitriol (10 nmol/l) with increasing dose of 3H-1,2-Dithiole-3-thione (D3T) (6.25–12.5–25–50 lmol/l) for 7 days. (A) Alkaline phosphatase
enzyme activity was measured, and the results were normalized by protein content and data show the average of three separate experiments per-
formed in duplicate. ***P < 0.001. (B) Ferritin H-chain expression was detected by Western blot as shown in upper panel, and after densitometry
the result was normalized to GAPDH, shown in lower panel. **P < 0.01, ***P < 0.001 (C) SMC were cultured in GM or in the presence of BGP
(10 mmol/l) and calcitriol (10 nmol/l) with additional D3T (50 lmol/l) for 4 days with or without negative control (NC) or H-ferritin (FtH)-specific
siRNA. Alkaline phosphatase enzyme activity was measured, and the results were normalized by protein content and data show the average of two
separate experiments performed in duplicate. ***P < 0.001. (D) To evaluate the efficiency of ferritin H-chain silencing protein expression was
detected by Western blot shown in upper panel, and the results of densitometry after normalizing to GAPDH are shown in lower panel.
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models [34]. It is suggested that calcitriol increases SMC mineraliza-
tion by increasing the RANKL/osteoprotegerin ratio [14]. Based on
the above mentioned evidence we used Pi and calcitriol to induce
osteoblast transition of SMC.
Ferritin is an ancient, large, spherical protein with highly con-
served three-dimensional structure and is the most important intra-
cellular iron handling machinery [35, 36]. The ferritins are a family of
proteins similar to spherical shells, designed to sequester and store
Fig. 5 Elucidation of mechanism of inhibition of smooth muscle cells
(SMC) differentiation to osteoblasts. (A) SMC were treated with b-glyc-
erophosphate (BGP) (10 mmol/l) and activated vitamin D3 (calcitriol)
(10 nmol/l) for 7 days and the cell lysates was used for in vitro measure-
ments. Apo- and holoferritin in addition to levimazole, a well-known ALP
inhibitor was used to evaluate the direct effects on enzyme activity.
Enzyme activity was measured in duplicate, ***P < 0.001. SMC were
cultured in growth medium (GM) or in the presence of BGP (10 mmol/l)
and calcitriol (10 nmol/l) with additional apo- or holoferritin (2 mg/ml)
for 7 days. (B) Alkaline phosphatase enzyme level was detected by Wes-
tern Blot, where loading control was performed by GAPDH. (C) Alkaline
phosphatase induction was visualized by immunofluorescence staining.
Blue colour represents the nuclei and red colour shows the expression of
alkaline phosphatase, magnification 4009. (D) Alkaline phosphatase
mRNA expression was detected by RT-PCR and results were normalized
by GAPDH mRNA content and data show the average of two separate
experiments performed in duplicate. **P < 0.01, ***P < 0.001.
Fig. 6 Ferroxidase activity of ceruloplasmin also inhibits the differentia-
tion of smooth muscle cells (SMC) to osteoblasts. SMC were treated
with b-glycerophosphate (BGP) (10 mmol/l) and activated vitamin D3
(calcitriol) (10 nmol/l) in the presence of increasing dose of ceruloplas-
min (1–3 mg/ml) for 7 days. (A) Alkaline phosphatase enzyme activity
was measured, and the results were normalized by protein content and
data show the average of two separate experiments performed in dupli-
cate. **P < 0.01, ***P < 0.001. (B) Cells were stained for alkaline
phosphatase enzyme activity, and representative parts of the slides were
selected, magnification 1009. (C) Alkaline phosphatase enzyme level
was detected by Western Blot, and GAPDH served as loading control.
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Fig. 7Mineralization of vascular smooth muscle cells induced by inorganic phosphate and calcium is inhibited by induction of ferritin. Calcification
occured by supplementation of growth medium (GM) with 1.2 mmol/l inorganic phosphate and 0.9 mmol/l calcium chloride. (A) Alizarin Red stain-
ing of the cells shows the mineralization process and the inhibition by increasing dose of iron and apoferritin. (B) Iron inhibits extracellular calcium
deposition of human aortic smooth muscle cells (SMC) in a dose-dependent manner, where apoferritin also prevents mineralization. Calcium content
of the cells was measured at 5 days and normalized by the protein content of the cells. (C) Iron and apoferritin attenuate up-regulation of osteocal-
cin induced by calcifying condition. SMC were cultured in GM or in calcification medium with increasing dose of ferric-(III)-ammonium citrate
(12.5–25–50 lmol/l) or 2 mg/ml apoferritin for 5 days. Data is derived from four separate experiments are shown as mean  SD, **P < 0.01;
***P < 0.0001. (D) Representative images of SMC with Alizarin red staining indicating the inhibition of mineralization with increasing dose of 3H-
1,2-Dithiole-3-thione (D3T). SMC were cultured in GM or in calcifying condition as described above or supplemented with 6.25, 12.5, 25 and
50 lmol/l D3T during 5 days. Exposure of SMC to D3T decreased the accumulation of calcium (E) and osteocalcin levels (F) in a dose-responsive
manner. Graphs are shown mean  SD of three separate experiments. **P < 0.01; ***P < 0.001. [Correction added on 26 January 2016 after first
online publication: Figure 7 was presented incorrectly and has been amended in this version.]
Fig. 8 Ferritin heavy chain (FtH) is the
main modulator of inhibition of mineraliza-
tion of vascular smooth muscle cells.
Smooth muscle cells (SMC) were trans-
fected with siRNA for FtH or negative con-
trol siRNA (NC) 24-hr before the
experiments. Cells were cultured in growth
media (GM) or calcifying media (additional
1.2 mmol/l inorganic phosphate and
0.9 mmol/l calcium to GM) alone or in the
presence of 25 lmol/l ferric-(III)-ammo-
nium citrate or 50 lmol/l D3T for 4 days.
(A) Iron exposure after FtH silencing failed
to attenuate calcium and (B) osteocalcin
accumulation. (C) D3T treatment after
silencing of FtH loses the capacity to inhi-
bit the calcium deposition and (D) osteo-
calcin accumulation in extracellular matrix.
(E) Western blot demonstrates the effi-
ciency of FtH silencing. GAPDH served as
loading control. Results are shown as
mean values  SD. ***P < 0.001.
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large amounts of iron in a safe, soluble and bioavailable form. Ferritin
is made of 24 subunits of two types (H, heavy and L, light chain)
whose proportion depends on the iron status of the cell, the tissue
and the organ. The two ferritin polypeptides are related, but FtH car-
ries a ferroxidase activity to oxidize Fe2+ to Fe3+ allowing safe incorpo-
ration of iron into the shell. Ferritin shells can store up to 4500 iron
atoms. Ferritin acts as a depot, sequestering excess iron and allowing
for the mobilization of iron when needed [35, 36]. Our understanding
of ferritin and its functions has markedly enhanced in the past decade
and novel functions other than regulation of iron metabolism and
homoeostasis are now attributed to ferritin [16, 37–41].
Previously, we reported that haeme and iron-mediated induction
of FtH prevents calcification and osteoblastic differentiation of SMC
induced by high Pi [16]. We reported that ferroxidase activity of FtH
was the key mediator of the observed inhibitory effects [16]. Impor-
tantly, we previously found that the induction of FtH was able to
Fig. 10 Suggested mechanism of how induction of ferritin via D3T pre-
vents smooth muscle cells mineralization. Transition of vascular smooth
muscle cells into osteoblast-like cells can be triggered by phosphate
[inorganic (Pi), b-glycerophosphate (b-GP)] or activated vitamin D3 (cal-
citriol). Pi taken up by sodium-phosphorus co-transporter-1 (Pit-1) acti-
vates core binding factor alpha-1 (Cbfa-1) responsible for the
expression of osteoblast-specific genes. Induction of ferritin heavy chain
with ferroxidase activity by 3H-1,2-Dithiole-3-thione (D3T) or iron abro-
gates the elevation of osteoblast-specific genes [transcription factor
Cbfa-1, osteocalcin (OC), alkaline phosphatase (ALP)] and the accumu-
lation of calcium in the extracellular matrix.
Fig. 9 Vitamin D analogues increases the osteoblastic transformation of
vascular smooth muscle cells (SMC). (A) SMC were cultured in growth
medium (GM) or in the presence of activated vitamin D3 (calcitriol)
(10 nmol/l) or with increasing dose of paricalcitol (1–4–10–40–
100 nmol/l) for 7 days. Alkaline phosphatase enzyme activity was mea-
sured, and the results were normalized by protein content and data
show the average of the triplicates, ***P < 0.001. (B) SMC were cul-
tured in GM or in the presence of paricalcitol (40 nmol/l) with additional
apo- or holoferritin (2 mg/ml) for 7 days. Enzyme activity was mea-
sured, and the results were normalized by protein content and data
show the average of two separate experiments performed in duplicate,
***P < 0.001. (C) Plasma samples from volunteers from our dialysis
centre were collected right after the haemodialysis session (control) and
after the administration of calcitriol/paricalcitol. After the administration
of drugs we waited 5 min. to reach a steady-state blood concentration
and then the samples were taken. SMC were treated with 1:1 ratio with
serum-free media and plasma samples for 5 days. Alkaline phosphatase
activity was measured, and the results were normalized by protein con-
tent and as a result of the high variability of patients values data show
maximum and minimum values besides of the median and interquartile
range, experiments were performed in duplicate.
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actively prevent the process of transformation of SMC into osteo-
blast-like cells and also inhibit osteoblast activity via down-regulation
of Cbfa-1 [16, 40], the main transcriptional factor mediating osteoge-
nesis and responsible for the induction of osteoblast-specific gene
expression [42]. Furthermore, ferritin did not affect Pi uptake via Pit1
(sodium-phosphorus co-transporter) [16]. These findings were the
first report to suggest a relationship between deranged iron metabo-
lism that is a frequent complication of CKD and vascular calcification.
Patients who are dependent on renal replacement therapy are suscep-
tible to iron deficiency for a multitude of reasons that include frequent
blood loss during haemodialysis and frequent diagnostic testing [43].
Moreover, increased expression and secretion of hepcidin in chronic
inflammatory states such as CKD translates to internalization and
degradation of ferroportin in lysosomes [44, 45]. The loss of ferro-
portin from cell membrane consequently ablates cellular iron export.
Evidence suggests that increased hepcidin levels can lead to func-
tional iron deficiency and subsequently anaemia by interrupting
intestinal iron absorption and inducing the retention of iron within
recycling reticuloendothelial macrophages. Therefore, it is evident
that CKD patients are at increased risk of developing iron scarcity
ensued by significant decrement in intracellular ferritin expression.
We suggested that such decrement exacerbates SMC transition to
osteoblasts in the uraemic environment. We were hence encouraged
to identify potential pharmacological agents that would be able to
induce ferritin expression and examine whether such induction via
chemical stimulants of ferritin would provide the same inhibitory
effects. To this end we examined the compound D3T that is known to
have anti-oxidant and cancer chemopreventive properties. We
demonstrate that D3T-induced up-regulation of FtH provides
inhibitory effects against high Pi- and calcitriol-mediated osteoblastic
differentiation of SMC. It should, however, be noted that D3T is not
currently approved for human use. However, it occurs naturally in
cruciferous vegetables. The oral administration of D3T is being con-
sidered for development as a potential drug for the chemoprevention
of hepatic and other carcinomas by the National Cancer Institute.
In conclusion, this study corroborates our previous findings and
validates FtH induction as a potent inhibitor of osteoblastic transfor-
mation of SMC. Given legitimate concerns regarding utilization of
excessive parenteral iron that may potentiate in excessive reactive
oxygen species formation, chemical induction of FtH via D3T may be
a novel preventive measure against vascular calcification. In support
of this premise, further studies to test this hypothesis in relevant ani-
mal models of vascular calcification is germane and timely given cur-
rent lack of reliable preventive and/or therapeutic modalities against
vascular calcification.
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